Last reviewed · How we verify
NP031112
At a glance
| Generic name | NP031112 |
|---|---|
| Also known as | tideglusib, NP12 |
| Sponsor | Noscira SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy (PHASE2)
- Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy (PHASE2, PHASE3)
- Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy (PHASE2)
- Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
- Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (PHASE2)
- Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (PHASE2, PHASE3)
- Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (PHASE2)
- Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |